United Therapeutics Corporation (UTHR) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped UTHR stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: United Therapeutics Corporation is well-positioned for future growth due to its strong drug pipeline, recent FDA approvals, and expansion into international markets. Despite near-term challenges such as supply chain issues and equity issuance, its innovative product strategy and potential for clinical and market successes lead us to maintain a bullish outlook. The saved 1-year distribution is P10 $500, P50 $650, and P90 $775.
Last analyzed · Model: gpt-4o
United Therapeutics Corporation Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $500 | Pessimistic plausible scenario |
| P50 | $650 | Median scenario |
| P90 | $775 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
United Therapeutics is showing strong growth fundamentals with significant recent developments, particularly FDA approval for a new drug. This positions the stock for potential upside. However, issues such as supply chain challenges and a recent equity raise introduce risks.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this UTHR analysis generated?
May 13, 2026.
Is this a guaranteed UTHR prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full UTHR stock analysis · UTHR sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.